Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapies for rare diseases and specialty conditions with significant unmet medical needs. The company operates primarily within the biopharmaceutical and specialty pharmaceuticals industries, combining late-stage clinical development with select commercial-stage assets. Its activities span drug development, regulatory advancement, and targeted commercialization, with a strategic emphasis on pediatric and oncology-related indications.
Protara’s primary business lines include the development of TARA-002, an investigational immunotherapy, and the commercialization of Choline Chloride Injection, an FDA-approved intravenous product used in parenteral nutrition. The company serves specialized healthcare providers, including hospitals and specialty clinics, and positions itself through a focus on niche indications, orphan disease pathways, and differentiated clinical development strategies. Protara was formed through the evolution of ArTara Therapeutics, which later adopted the Protara name as its pipeline and strategic scope expanded.
Business Operations
Protara’s operations are organized around two core areas: clinical-stage therapeutics development and commercial specialty pharmaceuticals. The company generates revenue primarily from sales of Choline Chloride Injection, which is used in adult and pediatric patients requiring parenteral nutrition and represents its only marketed product as of the most recent public disclosures. Clinical development activities are focused on advancing TARA-002 through late-stage trials.
The company’s development programs are conducted primarily in the United States, supported by clinical trial sites and third-party manufacturers. Protara controls intellectual property related to its therapeutic candidates and relies on contract research organizations, manufacturing partners, and distributors. Public sources confirm no material joint ventures; however, the company maintains standard commercial and clinical partnerships typical for a company at its stage. Data on additional subsidiaries beyond Protara Therapeutics, Inc. is inconclusive based on available public sources.
Strategic Position & Investments
Protara’s strategic direction centers on advancing TARA-002 for the treatment of lymphatic malformations and non–muscle-invasive bladder cancer, both areas where current treatment options are limited. Growth initiatives focus on completing clinical trials, pursuing regulatory approvals, and expanding the commercial footprint of its approved nutrition product to support funding for pipeline development.
The company has made targeted investments in manufacturing readiness and clinical infrastructure rather than broad-based acquisitions. Its portfolio is concentrated, with no confirmed diversified subsidiary structure or external portfolio companies. Protara’s involvement in emerging sectors is primarily within immunomodulatory therapies and rare pediatric diseases, aligning with orphan drug development incentives and expedited regulatory pathways.
Geographic Footprint
Protara Therapeutics is headquartered in New York, United States, and its operational footprint is primarily concentrated in North America. Clinical development activities are conducted through trial sites within the United States, with limited international exposure tied to regulatory and research collaborations.
The company does not report significant commercial operations outside the U.S., and its international presence is largely indirect, supported through suppliers, manufacturers, and clinical research partners. Based on publicly available filings, Protara does not maintain foreign offices or large-scale international subsidiaries.
Leadership & Governance
Protara is led by an executive team with experience in biotechnology, finance, and clinical development, emphasizing disciplined capital allocation and targeted advancement of late-stage assets. The leadership’s stated strategic vision focuses on delivering therapies for underserved patient populations while maintaining operational efficiency.
Key executives include:
- Jesse Shefferman – Chief Executive Officer
- Brian Korb – Chief Financial Officer
- Dr. Andrew Pecora – President and Co-Founder
Public disclosures indicate governance is overseen by a board with experience in healthcare, biotechnology, and capital markets. Detailed leadership philosophy beyond stated strategic objectives is limited; however, filings emphasize patient-focused development and regulatory execution.